Advertisement

Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px
Document › Details

Epizyme, Inc.. (1/7/13). "Press Release: Epizyme, Eisai and Roche to Develop EZH2 Companion Diagnostic. Collaboration Focused on Genetically Defined Lymphomas". Cambridge, MA.

Organisations Organisation Epizyme Inc.
  Organisation 2 Roche Molecular Diagnostics (RMD)
  Group Roche (Group)
Products Product PCR test (clinical diagnostics)
  Product 2 companion diagnostic test
Person Person Brown, Paul (Roche 201103 Head Roche Molecular Diagnostics)
     


Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, Eisai Co., Ltd. (ESALY) and Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a collaboration to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The collaboration's goal is to identify lymphoma patients with non-wild type EZH2, including the Y641 mutation. As demonstrated in Epizyme's Nature Chemical Biology publication, "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells [link]," lymphomas with genetic alterations of EZH2 require EZH2 enzymatic activity for proliferation, suggesting that EZH2 is a driving oncogene in these cancers and therefore an important therapeutic target.

Robert Gould, Ph.D., President and CEO of Epizyme added, "Epizyme is committed to the creation and commercialization of personalized therapeutics and companion diagnostics for patients with genetically defined cancers. Our collaboration with Roche to develop a companion diagnostic, in parallel with the clinical development of our EZH2 inhibitor with Eisai, demonstrates our commitment to accelerate the development of this innovative personalized therapeutic for lymphoma patients."

"Eisai and Epizyme are collaborating to develop an EZH2 inhibitor as a personalized therapeutic for patients with genetically defined cancers," commented Takashi Owa, Ph.D., Chief Innovation Officer, Eisai Product Creation Systems. "Working together with Roche enables us to target this important potential therapeutic for a genetically defined subset of lymphoma patients with high unmet need."

"Our collaboration with Epizyme and Eisai highlights Roche's position as the partner of choice for the development and commercialization of companion diagnostics for personalized healthcare. We are excited to be developing a diagnostic test that will support Epizyme and Eisai in the development of an EZH2 inhibitor as a new therapeutic for patients with genetically defined lymphomas," said Paul Brown, Head of Roche Molecular Diagnostics.


About Epizyme, Inc.

Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a class of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.

Epizyme has benchmark alliances with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit www.epizyme.com.


Media Contact

Megan Lustig
Spectrum
202.955.6222 ext. 2586
mlustig@spectrumscience.com

   
Record changed: 2016-09-18

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpctoc




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wpctoc Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px